Format

Send to

Choose Destination
J Pediatric Infect Dis Soc. 2018 Feb 19;7(1):71-77. doi: 10.1093/jpids/pix083.

Macrolides in Children With Community-Acquired Pneumonia: Panacea or Placebo?

Author information

1
School of Medicine, University of Western Australia, Crawley.
2
Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia.
3
Division of Infectious Diseases, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania.

Abstract

Pneumonia, most often caused by a respiratory virus, is common in childhood. Mycoplasma pneumoniae also is detected frequently, particularly in older children in the era of pneumococcal conjugate vaccination. Despite recommendations for β-lactam antibiotics, macrolide antibiotics, including erythromycin, clarithromycin, and azithromycin, are prescribed frequently to children with acute lower respiratory infection. However, the significance of detecting "atypical" pathogens, including M pneumoniae, in children remains contentious. Considering the potential for antibacterial and anti-inflammatory activities of macrolides, our understanding of the role of these drugs in acute and chronic infections and in inflammatory conditions is changing. Some observational data have revealed improved outcomes in adults and children with pneumonia who are prescribed macrolides, although its widespread use has led to increases in macrolide resistance in Streptococcus pneumoniae and M pneumoniae. Clinical trials to define the role of macrolides in pediatric acute respiratory infection must be prioritized.

PMID:
29096010
DOI:
10.1093/jpids/pix083
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for University of Western Australia Profiles and Research Repository
Loading ...
Support Center